Tyra Biosciences Statistics
Total Valuation
TYRA has a market cap or net worth of $1.49 billion. The enterprise value is $1.14 billion.
| Market Cap | 1.49B |
| Enterprise Value | 1.14B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TYRA has 59.68 million shares outstanding. The number of shares has increased by 4.40% in one year.
| Current Share Class | 59.68M |
| Shares Outstanding | 59.68M |
| Shares Change (YoY) | +4.40% |
| Shares Change (QoQ) | +6.88% |
| Owned by Insiders (%) | 2.68% |
| Owned by Institutions (%) | 69.84% |
| Float | 31.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.91, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.91 |
| Quick Ratio | 14.48 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.31% and return on invested capital (ROIC) is -30.05%.
| Return on Equity (ROE) | -45.31% |
| Return on Assets (ROA) | -28.46% |
| Return on Invested Capital (ROIC) | -30.05% |
| Return on Capital Employed (ROCE) | -44.73% |
| Weighted Average Cost of Capital (WACC) | 8.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 87 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +136.04% in the last 52 weeks. The beta is 0.77, so TYRA's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +136.04% |
| 50-Day Moving Average | 29.72 |
| 200-Day Moving Average | 29.45 |
| Relative Strength Index (RSI) | 32.27 |
| Average Volume (20 Days) | 660,336 |
Short Selling Information
The latest short interest is 9.25 million, so 15.49% of the outstanding shares have been sold short.
| Short Interest | 9.25M |
| Short Previous Month | 9.93M |
| Short % of Shares Out | 15.49% |
| Short % of Float | 29.71% |
| Short Ratio (days to cover) | 15.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -160.46M |
| Pretax Income | -148.57M |
| Net Income | -148.57M |
| EBITDA | -159.92M |
| EBIT | -160.46M |
| Earnings Per Share (EPS) | -$2.40 |
Balance Sheet
The company has $353.94 million in cash and $5.58 million in debt, with a net cash position of $348.36 million or $5.84 per share.
| Cash & Cash Equivalents | 353.94M |
| Total Debt | 5.58M |
| Net Cash | 348.36M |
| Net Cash Per Share | $5.84 |
| Equity (Book Value) | 353.66M |
| Book Value Per Share | 5.93 |
| Working Capital | 342.35M |
Cash Flow
In the last 12 months, operating cash flow was -$109.65 million and capital expenditures -$250,000, giving a free cash flow of -$109.90 million.
| Operating Cash Flow | -109.65M |
| Capital Expenditures | -250,000 |
| Depreciation & Amortization | 539,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -109.90M |
| FCF Per Share | -$1.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.40% |
| Shareholder Yield | -4.40% |
| Earnings Yield | -9.95% |
| FCF Yield | -7.36% |
Analyst Forecast
The average price target for TYRA is $50.82, which is 103.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.82 |
| Price Target Difference | 103.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |